Email Updates

Search form

You are here

AVAC in the News

  • A nightclub at Balaka Town is bulging with sex workers and their clients in search of pleasure and money. Within the compound, faint lights from florescent tubes are casting small beams onto an entrance into an adjoining room.

    January 13, 2020
    The Times Malawi
  • Over the past 30 years, advances ranging from medical technology to policy implementation have reduced new infections and suppressed the virus for those already living with HIV. There is a lot of excitement about technological innovations already on the market and those that will be available in the near future, including preexposure prophylaxis, or PrEP, which could soon be available as implants instead of daily pills. But progress in the global fight against HIV has been uneven, with the San Francisco Bay Area serving as an example of the global inequities in the disease burden.

    January 9, 2020
  • There is a problem with the decade's greatest medical moments. Most medical advances originate in rich countries, so they are sometimes out of reach for the world's poor — even when they address health problems more common in low-income countries. Treatment for HIV, for example, became available in the U.S. in 1996 but the rollout in Africa didn't begin until 2002. But some breakthroughs of the past decade have gone on to have a truly global impact.

    December 24, 2019
  • Inad never planned on being an AIDS advocate. He was set to become a lawyer, enrolling in law school in Mindanao, an island in southern Philippines. But in 2011, in the middle of his studies, he received the news that changed that trajectory. Inad found out he was HIV positive.

    December 16, 2019
    US News & World Report
  • As we approach 2020 — a pivotal year on many levels — we have more options and a clearer picture than ever of what must be done to end the HIV epidemic globally.

    December 3, 2019
  • Buried within a 2009 New England Journal of Medicine article on an HIV vaccine regimen was a sentence that would change the face of HIV vaccine research for the next decade: "the modified intention-to-treat analysis showed a significant, though modest reduction in the rate of HIV-1 infection as compared with placebo."

    December 3, 2019
    MedPage Today
  • Much of the progress in fighting HIV/AIDS is thanks to treatments such as antiretroviral (ARV) drugs. Alongside those, however, are other innovations that have provided models for broader moves towards universal health coverage.

    November 28, 2019
    Financial Times
  • The New HIV and Vaccine Microbicides Advocacy Society (NHVMAS) Wednesday urged the Federal Ministry of Health to reduce the age of access for both Sexual Reproductive Health (SRH) and HIV testing services to 14 years. The civil society organisation, which made this known at a round table discussion in Abuja, in collaboration with AVAC and GADO Agency LTD Nigeria, also urged the government to integrate SRH education into the curriculum of schools.

    November 20, 2019
    The Nation
  • The US government routinely sues pharmaceutical companies for making false claims, bilking Medicare, illegal kickbacks, and sloppy manufacturing practices. But on 6 November, the US Department of Justice (DOJ) filed suit against Gilead Sciences Inc. of Foster City, California, for reasons that cannot easily fit on a bumper sticker.

    November 8, 2019
  • The Trump administration, on behalf of the Department of Health and Human Services (HHS), filed a patent infringement lawsuit against pharmaceutical manufacturer Gilead Sciences, seeking damages from infringement on HHS patents related to HIV prevention medications, the agency announced on Wednesday night.

    November 7, 2019
    MedPage Today